Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10544MR)

This product GTTS-WQ10544MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10544MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3909MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ13930MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ10834MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ10372MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ11731MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ1393MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ7310MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ5584MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW